Argitalpenak (521) JUAN TAMARGO MENÉNDEZ argitalpenak

2024

  1. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

    European Heart Journal, Vol. 45, Núm. 36, pp. 3314-3414

  2. After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension

    European heart journal. Cardiovascular pharmacotherapy, Vol. 10, Núm. 5, pp. 371-373

  3. An account on the history of pharmacology in Spain

    Pharmacological Research

  4. Are NOACs always the best strategy in elderly AF patients?

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 10, Núm. 2, pp. 100-102

  5. Coexistent HCN4 and GATA5 Rare Variants and Atrial Fibrillation in a Large Spanish Family

    Canadian Journal of Cardiology, Vol. 40, Núm. 7, pp. 1270-1280

  6. Corrigendum to: An account on the history of pharmacology in Spain [Pharmacol. Res. 202 (2024) 107104 Pages 1–11 https://doi.org/10.1016/j.phrs.2024.107104] (Pharmacological Research (2024) 202, (S1043661824000483), (10.1016/j.phrs.2024.107104))

    Pharmacological Research

  7. Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect

    Pharmacological Research, Vol. 200

  8. Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations

    Expert Opinion on Investigational Drugs, Vol. 33, Núm. 9, pp. 967-978

  9. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 10, Núm. 3, pp. 219-244

  10. News in cardiovascular pharmacotherapy from the ACC.24 Meeting

    European heart journal. Cardiovascular pharmacotherapy

  11. Reply to Benndorff and DiFrancesco: Reliable human HCN4 single-channel recordings using the cell-attached configuration in expression systems

    Proceedings of the National Academy of Sciences of the United States of America

2023

  1. A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation

    The Journal of general physiology, Vol. 155, Núm. 1

  2. A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120

  3. An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps

    Cardiovascular Drugs and Therapy, Vol. 37, Núm. 6, pp. 1205-1223

  4. Concerns about aortic aneurysm or dissection risk should not cease fluoroquinolone use when clinically indicated

    European heart journal

  5. Diferencias de sexo en los beneficios de la anticoagulación en pacientes ancianos con fibrilación auricular: un subanálisis del estudio EMERG-AF

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 35, Núm. 4, pp. 252-260

  6. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 25, Núm. 4, pp. 1249-1276

  7. Editorial: Substance-based medical devices for human health: a challenge of efficacy, safety, and sustainability

    Frontiers in Drug Safety and Regulation

  8. Erratum: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (European Heart Journal - Cardiovascular Imaging (2022) 23:3 (e333–e465) DOI: 10.1093/ehjci/jeac106)

    European Heart Journal Cardiovascular Imaging

  9. Erratum: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy (European Heart Journal—Cardiovascular Pharmacotherapy (2022) 8: 4 (406–419) DOI: 10.1093/ehjcvp/pvac005)

    European Heart Journal - Cardiovascular Pharmacotherapy